hVIVO plc is a United Kingdom-based specialist early-stage drug development contract research organization (CRO) and human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base. It specializes in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its quarantine facility. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. The Company, through its subsidiary, operates an approximately 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. It also offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Company also provides industry-standard, temperature-controlled storage solutions for biological and clinical materials.